LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

432.95 -1.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

432.95

Max

446.12

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	21M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+59.74% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-611M 9.9B
Vorige openingsprijs	434.42
Vorige sluitingsprijs	432.95

Nieuwssentiment

By Acuity

34%

66%

108 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 feb 2026, 23:25 UTC

Populaire aandelen

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Winsten

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Marktinformatie

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Winsten

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Winsten

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Winsten

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Winsten

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Winsten

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Marktinformatie

Winsten

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Marktinformatie

Winsten

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Winsten

Acquisities, Fusies, Overnames

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Marktinformatie

Winsten

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Winsten

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Winsten

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Winsten

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

59.74% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 694.9 USD 59.74%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

108 / 351 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.